USPTO serial 97871034
AVANTEC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- TWAY, TATIANA R
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AVANTEC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
BRIAN S. BOYER, PH.D.
BRIAN S. BOYER, PH.D. SYNDICATED LAW, PC6655 LAKESHORE RDLEXINGTON, MI 48450United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Cardiovascular pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for an implantable device that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for an implantable vascular device that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for a stent that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for a vascular stent that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of coatings for use on medical devices that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of vascular disease; Pharmaceutical preparations for the treatment and prevention of restenosis; Pharmaceutical preparations for the treatment and prevention of inflammation; None of the foregoing used for veterinary purposes | ACTIVE | — |
| 010 | Medical devices for use in treating vascular disease; Medical devices for use in treating a thrombosis; Medical devices for use in treating cardiovascular disease; Medical devices for use in treating atherosclerosis; Medical devices for use in treating restenosis; Surgical instruments, namely, interventional devices; Surgical instruments, namely, thrombectomy devices; Surgical instruments, namely, vascular surgery devices; Surgical instruments, namely, atherectomy devices; Surgical instruments, namely, vascular retrieval systems; Surgical instruments, namely, vascular guide wires; Surgical instruments, namely, vascular coil devices; Surgical instruments, namely, vascular coil delivery systems; Surgical instruments, namely, drug delivery devices; Surgical instruments, namely, vascular dilation devices; Surgical instruments, namely, vascular stent devices; Surgical instruments, namely, vascular stent delivery systems; Surgical instruments, namely, balloon dilatation devices | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AVANTEC VASCULAR CORPORATION
- Other trademarks owned by AVANTEC VASCULAR CORPORATION
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named AVANTEC
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 24, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 24, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 24, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 24, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 20, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 11, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 11, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 24, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 22, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 22, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 22, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 16, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 4, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 20, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 1, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 1, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 31, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 16, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 21, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 21, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 21, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 21, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 12, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2023 | NWAP | NEW APPLICATION ENTERED | — |